Guardant Health Expands Cancer Diagnostics – Shield, Reveal, and Guardant360 Drive 44% Revenue Growth
Reading Time: 3 minutes
Guardant Health develops blood tests for cancer detection, treatment selection, and monitoring. In Q2, revenue increased by 44%, and the oncology test volume grew by 63%. Guardant360, Reveal, and Shield cover more stages of cancer care. Reveal's test volume grew by more than 100%, while Shield nearly quadrupled its screening revenue. For 2026, Guardant expects revenue growth of 36 to 38%. Shield is now commercially covered for approximately 94 million eligible Americans. Guardant Health (GH) aims to detect cancer earlier through blood...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
